- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05611957
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
September 29, 2023 updated by: Eli Lilly and Company
A Parallel-group, Phase 1, Open-label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Renal Impairment Compared With Healthy Participants
The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants.
The study will last up to 5 weeks, excluding screening.
Study Overview
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: ClinicalTrials.gov@lilly.com
Study Locations
-
-
California
-
Tustin, California, United States, 92780
- Orange County Research Center
-
-
Florida
-
Miami, Florida, United States, 33014-3616
- Clinical Pharmacology of Miami
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Nucleus Networks
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Normal Participants:
- Healthy male and female participants as determined by physical examination
- Participants with normal renal function assessed by estimated glomerular filtration rate (eGFR) ≥ 90 milliliter per minute (mL/min).
- Body mass index (BMI) ≥ 19.0 and ≤ 40.0 kilograms per meter squared (kg/m²)
- Male participants who agree to use contraception and female participants of child bearing potential must agree to use contraceptive methods and women not of child bearing potential can participate.
Participants with Renal Impairment:
- Have acceptable blood pressure (BP) and pulse rate, as determined by the investigator
- Participants with type 2 diabetes must have a glycated hemoglobin (HbA1c) ≥ 5.0% and ≤ 11.5%
- Are males or females with severe renal impairment as determined by a stable eGFR <30 mL/min, not requiring hemodialysis OR
- Are males or females with end-stage renal disease (have received hemodialysis for at least 3 months)
Exclusion Criteria:
- Have known allergies to LY3437943 or related compounds
- Have a current, functioning organ transplant. Nonfunctional renal allografts may be allowed
- Have any abnormality in the 12-lead electrocardiogram (ECG)
- Are women with a positive pregnancy test or women who are lactating
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY3437943 (Control)
LY3437943 administered subcutaneous (SC) to participants with normal renal function
|
Administered SC.
|
Experimental: LY3437943 (Severe Renal Impairment)
LY3437943 administered SC to participants with severe renal impairment
|
Administered SC.
|
Experimental: LY3437943 (End-Stage Renal Disease)
LY3437943 administered SC to participants with end-stage renal disease
|
Administered SC.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943
Time Frame: Predose up to 31 days postdose
|
PK: AUC0-∞ of LY3437943
|
Predose up to 31 days postdose
|
PK: Maximum observed concentration (Cmax) of LY3437943
Time Frame: Predose up to 31 days postdose
|
PK: Cmax of LY3437943
|
Predose up to 31 days postdose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 16, 2022
Primary Completion (Actual)
September 5, 2023
Study Completion (Actual)
September 5, 2023
Study Registration Dates
First Submitted
November 3, 2022
First Submitted That Met QC Criteria
November 3, 2022
First Posted (Actual)
November 10, 2022
Study Record Updates
Last Update Posted (Actual)
October 2, 2023
Last Update Submitted That Met QC Criteria
September 29, 2023
Last Verified
September 15, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18529
- J1I-MC-GZBL (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on LY3437943
-
Eli Lilly and CompanyRecruitingType 2 Diabetes | CKD | Overweight or ObesityUnited States, Italy, United Kingdom, Spain, Canada
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Japan
-
Eli Lilly and CompanyActive, not recruiting
-
Eli Lilly and CompanyRecruitingObesity | Overweight | Osteo Arthritis KneeUnited States, Canada, Spain, Australia, Mexico, United Kingdom
-
Eli Lilly and CompanyRecruitingObesity | Overweight | Obstructive Sleep Apnea | Type 2 DiabetesAustralia, United States, Mexico, Spain, India, Brazil, Romania, Taiwan, Argentina
-
Eli Lilly and CompanyRecruitingCardiovascular Diseases | ObesityUnited States, Australia, Mexico, Spain, Canada, Hungary, Argentina, Puerto Rico, Poland, Slovakia
-
Eli Lilly and CompanyNot yet recruitingDiabetes Type 2United States, India, Mexico, Puerto Rico
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyRecruiting
-
Eli Lilly and CompanyCompleted